Skip to main content

Hypersensitivity

5
Pipeline Programs
8
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Bayer
BayerLEVERKUSEN, Germany
3 programs
2
Butenafine HCl 1%Phase 31 trial
Butenafine HCl 1%Phase 31 trial
IopromideN/A1 trial
Active Trials
NCT04605471Completed132,850Est. Mar 2021
NCT04531813Completed32Est. Jul 2013
NCT04531540Completed225Est. Oct 2013
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
1
Mometasone furoate drug formulationPhase 1
Carvedilol immediate release onlyN/A
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
SugammadexPhase 1
MSD
MSDIreland - Ballydine
1 program
1
SugammadexPhase 11 trial
Active Trials
NCT02028065Completed382Est. Jul 2014
GSK
GSKLONDON, United Kingdom
2 programs
Carvedilol immediate release onlyN/A1 trial
Mometasone furoate drug formulationPHASE_11 trial
Active Trials
NCT01316952Completed1Est. Mar 2011
NCT02588326Completed80Est. Apr 2021
KeraNetics
KeraNeticsNC - Winston-Salem
1 program
KeraStat® CreamN/A1 trial
Active Trials
NCT04058054Completed22Est. Aug 2019
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
1 program
Egg oral immunotherapyPHASE_22 trials
Active Trials
NCT01846208Completed92Est. Sep 2018
NCT00461097Completed55Est. Dec 2013

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BayerButenafine HCl 1%
BayerButenafine HCl 1%
Allergy TherapeuticsEgg oral immunotherapy
Allergy TherapeuticsEgg oral immunotherapy
GSKMometasone furoate drug formulation
MSDSugammadex
BayerIopromide
KeraNeticsKeraStat® Cream
GSKCarvedilol immediate release only

Clinical Trials (9)

Total enrollment: 133,739 patients across 9 trials

NCT04531540BayerButenafine HCl 1%

Study to Determine Skin Irritation and/or Sensitization Potential of an Antifungal Cream Containing Trolamine (Repeated Insult Patch Test)

Start: Sep 2013Est. completion: Oct 2013225 patients
Phase 3Completed
NCT04531813BayerButenafine HCl 1%

Study to Determine Skin Irritation Potential of an Antifungal Cream Containing Trolamine After Repeated Skin Application (Cumulative Irritation Patch Test)

Start: Jun 2013Est. completion: Jul 201332 patients
Phase 3Completed
NCT01846208Allergy TherapeuticsEgg oral immunotherapy

Baked Egg or Egg Oral Immunotherapy for Children With Egg Allergy

Start: Jul 2013Est. completion: Sep 201892 patients
Phase 2Completed
NCT00461097Allergy TherapeuticsEgg oral immunotherapy

Oral Immunotherapy for Childhood Egg Allergy

Start: May 2007Est. completion: Dec 201355 patients
Phase 2Completed
NCT02588326GSKMometasone furoate drug formulation

Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays

Start: Sep 2018Est. completion: Apr 202180 patients
Phase 1Completed
NCT02028065MSDSugammadex

A Study to Evaluate the Incidence of Hypersensitivity After Administration of Sugammadex in Healthy Participants (MK-8616-101)

Start: Jan 2014Est. completion: Jul 2014382 patients
Phase 1Completed
NCT04605471BayerIopromide

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Start: Oct 2020Est. completion: Mar 2021132,850 patients
N/ACompleted
NCT04058054KeraNeticsKeraStat® Cream

Skin Prick Test of KeraStat® Cream

Start: Jul 2019Est. completion: Aug 201922 patients
N/ACompleted
NCT01316952GSKCarvedilol immediate release only

Coreg and HSRs-Updated Analysis

Start: Jun 2010Est. completion: Mar 20111 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.